Just weeks after sharing that it was planning cost cuts that would include layoffs, Prothena has announced a 63% workforce reduction. That reduction likely includes the 91 people the Dublin-headquartered biotech disclosed it was letting go in Brisbane, California, via a Worker Adjustment and Retraining Notification notice earlier this month.
All entries for: Home
June 23, 2025
Prothena - Dublin
Layoffs
Dublin, IE
51-200 employees
Disease Area: Multiple, Neurological Diseases, Rare Diseases
Drug Type: Biologic, Small Molecule
June 20, 2025
BioNTech
Discontinued Research, Layoffs
Gaithersburg, MD
5,001-10,000 employees
In conjunction with its decision to discontinue a study for one of its CAR T candidates, BioNTech will close down a cell therapy facility in Gaithersburg, Maryland, and lay off 63 employees at the site, according to a June 13 WARN notice and reporting from Fierce Pharma on Thursday.
Disease Area: Immune Diseases
Drug Type: Biologic, Small Molecule
June 16, 2025
Gilead Sciences - Oceanside
Layoffs
Oceanside, CA
10,001-50,000 employees
Gilead Sciences cut 36 employees in Oceanside, California, effective Aug. 15, according to a Worker Adjustment and Retraining Notification notice. The location supports clinical manufacturing and process development for the Foster City, California–based pharma and subsidiary Kite Pharma.
Disease Area: Antiviral, Chronic Disease, Multiple, Oncology
Drug Type: Biologic, Small Molecule
June 16, 2025
ImmunityBio
Layoffs
Woburn, MA
501-1,000 employees
The San Diego–based biotech is letting go of three employees at their Woburn, Massachusetts, effective from July 29 to Aug. 12, according to a Worker Adjustment and Retraining Notification notice.
Disease Area: Infectious Diseases, Multiple, Oncology
Drug Type: Biologic, Small Molecule
June 13, 2025
ADC Therapeutics
Layoffs
New Providence, NJ
201-500 employees
To cut costs and help extend its cash runway into 2028, ADC Therapeutics is laying off about 30% of its global workforce, closing its U.K. research facility and trimming its pipeline, the company announced June 12. The Switzerland-based biotech had 265 employees as of Dec. 31, according to its annual report, meaning the layoffs could affect around 80 employees.
Disease Area: Oncology
Drug Type: Biologic, Small Molecule
June 12, 2025
Genentech
Layoffs
San Francisco, CA
10,001-50,000 employees
Laying off 143 workers at their headquarters in South San Francisco.
Disease Area: Cardiology, Immune Diseases, Multiple, Neurological Diseases, Oncology, Rare Diseases
Drug Type: Biologic, Small Molecule
June 12, 2025
Vertex Pharmaceuticals
Layoffs
Providence, RI
5,001-10,000 employees
Just months after shelving its cell therapy–device combo for type 1 diabetes, Vertex Pharmaceuticals is parting ways with 140 employees, according to a Worker Adjustment and Retraining Notification letter dated June 6. The layoffs will heavily focus on the company’s Rhode Island operations, where 125 employees will be affected, as per the state’s WARN posting. There, Vertex is consolidating its three Providence sites, which currently form somewhat of an “integrated campus” in the city, into just one location, as per the WARN letter. “We presently expect this action to be permanent,” wrote Camilo Cobos, the biotech’s vice president of human resources.
Disease Area: Endocrinology, Hematology, Multiple, Rare Diseases, Respiratory Diseases
Drug Type: Biologic, Small Molecule
June 11, 2025
Recursion Pharmaceuticals
Layoffs
Salt Lake City, UT
201-500 employees
Recursion Pharmaceuticals will lay off roughly 20% of its workforce, affecting some 160 employees, in a bid to extend its cash runway.
Disease Area: Multiple, Oncology, Rare Diseases
Drug Type: Small Molecule
June 10, 2025
SciSparc
Neutral Outlook
Tel Aviv, Israel
1-50 employees
The passage of the Inflation Reduction Act, or the IRA, of 2022 further affects Medicare reimbursement. The IRA has three key elements reforming Medicare drug-pricing policy. The implementation of certain elements of the IRA are still forthcoming, as outlined below, so the specific implications for biopharmaceutical pricing and reimbursement are yet to be determined. Likewise, SciSparc is unable to predict potential modification, amendment, or repeal of the IRA, though some predict that challenges may be made as different provisions are enacted.
Disease Area: Chronic Disease, Multiple, Neurological Diseases, Psychiatry, Respiratory Diseases
Drug Type: Small Molecule
June 9, 2025
Ikena Oncology
Neutral Outlook
Boston, MA
1-50 employees
For example, on August 16, 2022, the Inflation Reduction Act of 2022 (“IRA”) was signed into law, which among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. The IRA also eliminates the “donut hole” under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost and creating a new manufacturer discount program. It is unclear how other healthcare reform measures of the second Trump administration, if any, will impact our business.
Disease Area: Oncology
Drug Type: Biologic